Health Ministry Tightens Stem Cell Therapy Rules, Restricts Autism Use to Trials
Union Health Ministry advisory restricts stem cell therapy as standard care to approved indications, limits autism use to clinical trials, and warns of penalties for non-compliance.
The Ministry of Health & Family Welfare has issued an advisory to all States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010, laying down strict conditions for the use of stem cell therapy in clinical practice.
Under the framework reiterated in the advisory dated 16 September 2026, stem cell therapy may be offered as standard care in routine clinical practice only for disease conditions and indications that appear on a list approved by the Ministry. For Autism Spectrum Disorder (ASD), the therapeutic use of any type of stem cell will remain confined to duly approved clinical trials, in line with the National Guidelines for Stem Cell Research, 2017, issued jointly by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), along with other applicable government instructions.
The advisory follows the Supreme Court's judgment of 30 January 2026 in Yash Charitable Trust & Ors. v. Union of India & Ors. It notes that the court, in Para 151(xiii) of its ruling, held that non-compliance with the statutory mandate must attract consequences, including professional misconduct under Regulation 7.22 of the IMC Regulations, 2002, as well as action under Sections 32 and 40 of the Clinical Establishments Act, which provide for cancellation of registration and penalty.
States and Union Territories have been asked to widely disseminate the Supreme Court's directions to all State and District Regulatory Authorities and to government and private clinical establishments involved in stem cell research, treatment, promotion or administration, so that the applicable framework is strictly followed.
The regulatory position was reinforced by the National Medical Commission (NMC) in its advisory dated 5 September 2026, which reiterated that stem cell therapy may be offered as standard clinical care only for approved indications. The NMC stated that unauthorised administration, prescription, promotion or advertisement of stem cell therapy beyond the approved indications would amount to professional misconduct.
State Medical Councils have been advised to examine cases of alleged violations brought to their notice and, where professional misconduct by a Registered Medical Practitioner is established after due process, to take appropriate disciplinary action in accordance with the applicable statutory and regulatory provisions.